EXPERT EVALUATION OF ANTI-TUMOR DRUGS USED IN THE THERAPY OF PATIENTS WITH PROSTATE CANCER

Nigmatullina Y.U.,Rostova N.B.,Dudarenkova M.R.,Gorbunova E.S.

DOI: https://doi.org/10.26787/nydha-2686-6838-2024-26-1-152-157

2024-01-31

Abstract:Socially significant diseases are the subject of close attention from the state, which takes on an invaluable share of responsibility for maintaining stability in the processes of providing medical care and drug supply. Limited budgetary resources and the high cost of anticancer therapy create unfavorable conditions for organizing the proper level of drug care for patients with cancer, which forces healthcare participants to find ways and tools that would open up opportunities to increase drug availability in compliance with the principles of rational use of financial resources and the involvement of pharmaceutical specialists along with other healthcare participants. Prostate cancer is one of the most difficult to treat and, as a result of its development, leads to disability among the population. Moreover, the etiology of prostate tumors has not been determined to this day, which causes a high level of diagnosis in the final stages with the manifestation of metastases and aggravation of existing concomitant diseases (with an average patient age of 70 years), which makes it difficult to choose therapy aimed more at maintaining quality life rather than a complete cure. In connection with the above, the choice of therapeutically effective and safe drugs used in the treatment of malignant neoplasms of the prostate gland is one of the key points in providing adequate therapy and improving the quality of life of patients. This study is devoted to the method of expert assessment of the effectiveness and safety of anticancer drugs used in the treatment of malignant neoplasms of the prostate gland as a tool for creating rational lists for the treatment of malignant neoplasms of the prostate gland under conditions of a limited budget. Presents: stages of expert assessment; the structure of the questionnaire used to collect data on the therapeutic efficacy and safety of anticancer drugs; parameters for assessing the competence of oncologists-urologists; parameters for assessing drugs used in the treatment of malignant neoplasms of the prostate gland (therapeutic effectiveness, adverse reactions, ease of use, compatibility with other drugs, tolerability of drugs by patients with prostate cancer), as well as the results of expert assessment in the form of lists of effective and safe drugs for each stage prostate cancer, used at the inpatient and outpatient level of medical care, as well as offered in a pharmacy organization.